v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Grant revenue $ 0 $ 1,917,491
Operating expenses:    
Research and development 5,135,419 4,837,798
General and administrative 2,975,105 2,382,577
Total operating expenses 8,110,524 7,220,375
Loss from operations (8,110,524) (5,302,884)
Other income (expense):    
Other expense (1,021) (135)
Interest income 147,387 408,985
Total other income, net 146,366 408,850
Net loss $ (7,964,158) $ (4,894,034)
Per share information:    
Net loss per share of common stock, basic and diluted (in dollars per share) $ (0.86) $ (0.56)
Weighted average shares outstanding, basic and diluted (in shares) 9,258,319 8,702,719
Net loss:    
Net unrealized loss on marketable securities $ (6,024) $ (34,974)
Total comprehensive loss $ (7,970,182) $ (4,929,008)